We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Nov 2023
  • Code : CMI6064
  • Pages :150
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Global nausea medicine market is expected to grow from US$ 2.8 Bn in 2023 to US$ 4.3 Bn by 2030, at a CAGR of 6.3% during the forecast period 2023-2030.

The growth of the global nausea medicine market is being driven by a number of factors, including the increasing prevalence of nausea and vomiting, the growing demand for over-the-counter (OTC) nausea medicines, and the increasing number of new product launches.

Nausea and vomiting are common symptoms that are caused by a variety of conditions, including motion sickness, pregnancy, chemotherapy, and infections. The increasing prevalence of these conditions is driving the demand for nausea medicines.

Global Nausea Medicine Market Regional Insights

  • North America is the largest market for nausea medicine, accounting for a market share of over 30% in 2023. The high prevalence of cancer and gastrointestinal diseases in the region is the major driver for the market growth. Increasing geriatric population and the high adoption of over-the-counter (OTC) medications are also contributing to the market growth in North America. For instance, January 2023, according to American Cancer Society, about 1.9 Mn new cancer cases are expected to be diagnosed in the U.S. in 2023. Moreover, approximately 609,820 deaths from cancer are expected in the U.S. in 2023, which are about 1,670 deaths per day.
  • Europe is the second-largest market for nausea medicine, accounting for a market share of over 25% in 2023. Rising incidence of cancer and gastrointestinal diseases in the region is driving the growth of the market. Increasing awareness about the benefits of nausea medicine and the favorable reimbursement policies are also contributing to the market growth in Europe.
  • Asia Pacific is the fastest-growing market for nausea medicine, with a CAGR of over 15% during the forecast period. The high prevalence of gastrointestinal diseases and motion sickness in the region is the major driver for the market growth. Increasing disposable income and the growing demand for innovative and effective nausea medicines are also contributing to the market growth in Asia Pacific.

Figure 1. Global Nausea Medicine Market Share (%), By Region, 2023


To learn more about this report, request a free sample copy

Analyst View of the Global Nausea Medicine Market:

Global nausea medicine market is a mature market but still holds potential for growth. The market has several established players with popular brands dominating the shelves. However, increasing demand from emerging markets and an aging global population will drive new opportunities. North America has traditionally been the largest market due to strong brand awareness and marketing budgets of major players. But Asia Pacific is expected to grow the fastest due to a rise in healthcare expenditure and western influence. Generics have made significant advances in recent years, posing a challenge to large pharmaceutical corporations with patented medications nearing the end of their shelf life. At the same time, the need to improve formulations in order to match changing consumer needs and preferences opens up avenues for product innovation. Stricter norms around drug safety and efficacy pushed by regulatory bodies worldwide could retard growth prospects for some market players. Alternative therapies and home remedies especially in developing nations may curb demand for pharmaceutical products to some extent. Overall, a mix of demographic and economic trends bode well for continued expansion of this market.

Global Nausea Medicine Market Drivers

  • Increasing prevalence of nausea: Nausea is a common symptom which is associated with various medical conditions, such as chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), motion sickness, and pregnancy-related nausea. The growing prevalence of these conditions creates a high demand for effective nausea medicines. For instance, on March 2023, according to the Pharmaceutical Journal, 90% of individuals will have motion sickness at some time in their life. However, the frequency and occurrence of this condition might differ greatly, based on several factors including age and gender, individual sensitivity, and transportation method. Motion sickness is more common in young individuals and children because of the way their ears function. Young people's bodies and eyes won't perceive motion, but their inner ears will. This might lead to nausea, vomiting, exhaustion, an upset stomach, or cold sweats. It is uncommon in younger children under two years old and is believed to peak between the ages 3 and 12.
  • Advancements in drug formulations: Pharmaceutical companies are continuously investing in research and development (R&D) to develop improved formulations of nausea medicines. The introduction of new drug delivery systems, such as oral dissolvable tablets, transdermal patches, and fast-acting injectable, has enhanced patient compliance and convenience, thus driving the market growth.
  • Increasing geriatric population: The elderly population is more susceptible to nausea due to various factors such as medication side effects, comorbidities, and age-related physiological changes. As the global population continues to age, the demand for nausea medicines among the geriatric population is expected to rise, thus driving the market growth.
  • Growing awareness and diagnosis: Increased awareness of nausea as a symptom and its impact on quality of life has led to a higher number of patients seeking medical attention and diagnosis. As a result, healthcare professionals are prescribing more nausea medicines, thereby driving the market growth. For instance, in July 2023, International Foundation for Gastrointestinal Disorders (IFFGD) announced awareness for Gastroparesis Awareness Month to shed light on the varied impact on the quality of life for individuals. Gastroparesis (GP) is a condition of slowed stomach emptying with no intestinal blockage with the most common symptom including nausea and vomiting.

Global Nausea Medicine Market Opportunities

  • Development of targeted therapies: There is an opportunity for pharmaceutical companies to develop more targeted therapies for specific causes of nausea. By identifying and targeting the underlying mechanisms that trigger nausea in different conditions such as chemotherapy-induced nausea, pregnancy-related nausea, or postoperative nausea, companies can provide more effective and tailored treatments. For instance, in May 2022, Taiho Pharmaceutical Co., Ltd., a Japan based pharmaceutical company, stated that their selective NK1 receptor antagonist antiemetic medicine "Arokaris I.V. infusion 235mg" has been added to the National Health Insurance (NHI) reimbursement pricing list. Arokaris is an antiemetic medication with a specific NK1 receptor antagonist that has been developed to reduce chemotherapy-induced nausea and vomiting.
  • Expansion into emerging markets: The nausea medicine market has significant growth potential in emerging markets. As these markets experience improvements in healthcare infrastructure and increasing disposable incomes, thereby the demand for nausea medicines is expected to rise. Pharmaceutical companies can focus on expanding their presence in these regions, in adapting their products to meet the specific needs and preferences of the local population.
  • Combination therapies: There is an opportunity to develop combination therapies that address multiple aspects of nausea. For example, combining antiemetic drugs with drugs targeting specific receptors or pathways involved in nausea can lead to improved efficacy and better control of symptoms. Pharmaceutical companies can explore such combinations to enhance the treatment options available to patients. For instance, in January 2023, Glenmark Pharmaceuticals Ltd., an innovation-driven global pharmaceutical company, launched AKYNZEO V., a novel intravenous injection formulation, in India as part of an exclusive licensing agreement with Helsinn, a Sweden based biopharma group company. AKYNZEO I.V. is a ready-to-dilute intravenous injection that is a fixed dose combination of palonosetron (0.25 mg) and fosnetupitant (235 mg).
  • Non-pharmacological interventions: Non-pharmacological interventions, such as acupuncture, acupressure, relaxation techniques, and dietary modifications, have shown promise in managing nausea in certain conditions. There is an opportunity to further explore and develop these non-pharmacological interventions as adjunct therapies or alternative options for patients who prefer non-drug approaches.

Nausea Medicine Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 2.8 Bn
Historical Data for: 2023 - 2030 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.3% 2030 Value Projection: US$ 4.3 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East:  GCC, Israel and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Antihistamines, Anticholinergics, Serotonin Antagonists, Dopamine Antagonists, Cannabinoids, and Others
  • By Route of Administration: Oral, Injectable, Transdermal, Rectal, and Others
  • By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others
Companies covered:

GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company

Growth Drivers:
  • Increasing prevalence of nausea
  • Advancements in drug formulations
  • Increasing geriatric population
  • Growing awareness and diagnosis
Restraints & Challenges:
  • Adverse effects and safety concerns
  • High cost of nausea medicines
  • Lack of targeted therapies for specific causes
  • Limited efficacy in some cases

Global Nausea Medicine Market Trends

  • Increasing focus on patient-centric approaches: There is a growing emphasis on patient-centric approaches in healthcare, including the management of nausea. The focus is shifting towards understanding patient preferences, needs, and experiences to develop tailored treatment options. This trend promotes shared decision-making, patient engagement, and personalized care in nausea medicine.
  • Integration of digital health solutions: The integration of digital health solutions, such as mobile applications, wearable devices, and remote monitoring tools, is gaining momentum in the nausea medicine market. These technologies offer opportunities for symptom tracking, medication reminders, and real-time communication with healthcare providers, thus enhancing patient adherence and improving outcomes. For instance, in August 2021, Reliefband, a company that develops wearable technology to prevent and treat symptoms of nausea and vomiting, launched Reliefband Sport, a new waterproof wearable therapeutic device that is IPX7 certified. In addition to treating post-operative nausea, Reliefband Sport also prevents and relieves nausea and vomiting that is related to motion sickness, pregnant morning sickness, anxiety, hangovers, headaches diagnosed by a doctor, and chemotherapy.
  • Rise in natural and herbal remedies: Increasingly, individuals are seeking natural and herbal remedies for managing nausea. This trend is driven by a desire for alternative therapies and a preference for more natural products. As a result, there is a growing market for natural antiemetic remedies, including herbal supplements and essential oils.

Global Nausea Medicine Market Restraints

  • Adverse effects and safety concerns: Nausea medicines, like any other medications, can have side effects and safety concerns. Common side effects that are associated with antiemetic drugs include drowsiness, dizziness, constipation, and dry mouth. In some cases, there may be more severe adverse effects. Safety concerns and the potential for adverse effects may impact patient compliance and limit the use of certain medications. For instance, side effects of nausea relief medicine include fainting, swelling of face, arms, and legs, weight loss among others. Some uncommon adverse effects include diarrhea, stomach or abdominal pain.
  • High cost of nausea medicines: Some nausea medicines, especially newer and innovative therapies, can be expensive. High treatment costs can limit access to these medications, particularly for patients without adequate insurance coverage or in regions with limited healthcare resources. The cost factor can be a significant restraint for patients and healthcare systems, thus affecting the overall adoption and utilization of nausea medicines.
  • Lack of targeted therapies for specific causes: While there are various nausea medicines available, there may be a lack of targeted therapies for specific causes of nausea. Different conditions, such as chemotherapy-induced nausea, pregnancy-related nausea, or postoperative nausea, have unique underlying mechanisms. The absence of condition-specific treatments may limit the effectiveness of available nausea medicines in certain patient populations.
  • Limited efficacy in some cases: Nausea is a complex symptom influenced by various factors, including individual patient characteristics and the underlying cause. While many nausea medicines are effective for managing symptoms, there may be instances where the efficacy is limited or varies among patients. Finding the right treatment approach and optimizing efficacy for all patients can be challenging.

Counterbalance: The market players should provide the required medical coverage for the patients to bear the high cost of nausea medicines. At the time of manufacturing such products, the market players should be aware in reducing the side effects of the nausea medicines.

Recent Developments

New product launches

  • Akynzeo IV (fosnetupitant/palonosetron) is a fixed-dose combination injection that is used to prevent chemotherapy-induced nausea and vomiting (CINV). It was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is available in the United States.
  • Barhemsys (amisulpride) is an intravenous solution that is used to treat and prevent postoperative nausea and vomiting (PONV). It was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is available in the U.S.
  • In September 2022, Heron Therapeutics, a commercial-stage biotechnology company announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Acquisition and partnerships

  • In January 2023, Helsinn Group, a global biopharma company, and Immedica Pharma AB, a pharmaceutical company focused on the commercialization of rare and specialty care products, have announced an exclusive long-term license and distribution agreement for the commercialization of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets: AKYNZEO (Netupitant-Palonosetron fixed combination) and AKYNZEO (Palonosetron).
  • In March 2021, Starton Therapeutics Inc., a U.S.-based privately held clinical-stage biopharmaceutical company, and Haisco Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, announced that they have entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ, a once-weekly transdermal olanzapine delivery system in development for nausea and vomiting, in Mainland China.
  • In January 2022, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the acquisition of SANCUSO (granisetron transdermal patch), an U.S. FDA-approved oncology-supportive care medicine, from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company focused on discovering and delivering novel medicines. SANCUSO is the first and only prescription patch authorized by the US FDA to reduce nausea and vomiting in patients undergoing specific forms of chemotherapy.

Figure 2. Global Nausea Medicine Market Share (%), By Drug Class, 2023


To learn more about this report, request a free sample copy

Top Companies in Global Nausea Medicine Market

  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc.
  • Eli Lilly and Company

Definition: Nausea medicine, also known as antiemetic medication, is a type of pharmaceutical drug or treatment designed to relieve or prevent nausea and vomiting. Nausea is the unpleasant sensation of feeling like you're about to vomit, and vomiting is the act of expelling the contents of the stomach through the mouth. Nausea medicine can be prescribed by a healthcare provider or purchased over-the-counter and may work through various mechanisms, such as blocking specific receptors in the body, reducing stomach acidity, or affecting the central nervous system. These medications are commonly used to alleviate symptoms associated with conditions like motion sickness, chemotherapy-induced nausea and vomiting, pregnancy-related nausea (morning sickness), and post-operative nausea, among others.

Frequently Asked Questions

Side Effects, Lack of Efficacy, Alternative Therapies, Regulatory Challenges and Pricing and Access

Increasing Prevalence, Aging Population, Advancements in Medicine, Expansion of Treatment Options and Increasing Awareness

The leading component segment in the market is typically pharmaceutical drugs or active pharmaceutical ingredients (APIs).

GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Eli Lilly and Company

North America and Europe have been leading regions in the market due to advanced healthcare infrastructure, high healthcare spending, and a higher prevalence of conditions causing nausea.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo